美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

225.29

+5.342.43%

成交量：27.51萬

成交額：6,156.96萬

市值：243.44億

市盈率：-60.84

高：225.97

開：223.88

低：220.87

收：219.95

資料載入中...

總覽公司新聞公告

回港中概股午後走強，金山雲(03896.HK)漲超13%，百濟神州(06160.HK)漲超7%，萬國數據(09698.H

A股創新藥概念持續走強，百濟神州、諾誠健華、錦波生物均創出歷史新高，科倫藥業、益方生物、澤璟製藥、華東醫藥、恆瑞醫藥等漲

百濟神州：盤中漲超 5% 24 年收入增 55%

百濟神州美股專利糾紛勝訴午盤漲近6%

【港股午評：AI股強勢，恒生科技指數漲超1%，金山雲飆升15%】截至半日收盤，恒指漲0.22%報22056點，恒生科技指數漲1.06%，國企指數跌0.37%。恒指半日成交1127億港元，南下資金半日淨買入港股34.34億港元。首季盈利表現遜預期，內銀股集體下挫，盛京銀行跌超6%，工商銀行、郵儲銀行、招商銀行、農業銀行跌超4%，建設銀行跌近4%。 AI概念股集體走強，金山雲大漲超15%，邁富時漲超8%，第四範式漲超6%，美圖、金山軟件漲超5%，小米漲近5%。小米今天開源首個為推理(Reasoning)而生的大模型“Xiaomi MiMo”，聯動預訓練到後訓練，全面提升推理能力。機器人概念股集體走強，微創機器人漲超9%，速騰聚創漲超7%。工信部近日表示，人形機器人是人工智能賦能新型工業化的高級載體，將推動人形機器人產業創新發展，以人形機器人小切口帶動人工智能大產業發展，高水平賦能新型工業化。百濟神州漲超5%；美藥企專利指控被判無效。迪生創建(0113.HK)獲主席潘迪生溢價50.6%提私有化，今日復牌大漲，半日收漲43.1%。友邦漲近6%；首季新業務價值升13%至15億美元，香港業務新業務價值升16%。

百濟神州午前漲近6% 美國專利糾紛勝訴公司去年業績取得強勁增長

港股醫藥高開低走，恒生醫藥ETF一度漲超1%

Ofweek维科网

港股異動 | 百濟神州(06160)漲超6% 美國專利糾紛勝訴公司去年業績取得強勁增長

港股生物技術股多數走強，康希諾生物(06185.HK)漲超10%，百濟神州(06160.HK)漲超6%，諾誠健華(099

夜盤異動丨百濟神州漲超6%，美藥企專利指控被判無效

老虎资讯综合

百濟神州4月29日成交額為7993.13萬美元

百濟神州美國專利糾紛勝訴，創新藥滬深港ETF漲超1%，創新藥龍頭拐點或現？

每日经济新闻

港股創新藥板塊盤初拉昇，百濟神州漲超6%

南方财经网

百濟神州(06160)因受限制股份單位獲歸屬而發行21.47萬股

百濟神州美國專利糾紛勝訴 USPTO裁定Pharmacyclics專利無效

百濟神州：關於公司涉及訴訟的進展

百濟神州(06160)美國專利糾紛勝訴 USPTO裁定Pharmacyclics專利無效

索托克拉上市申請獲受理，百濟神州血液腫瘤管線或迎又一重磅新品

索托克拉上市申請獲受理百濟神州又一款血液腫瘤自研產品有望面市

中国网财经

百濟神州2024年虧損減少至49.8億元，收入增長56.2%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":225.2925,"timestamp":1747337215995,"preClose":219.95,"halted":0,"volume":275086,"delay":0,"floatShares":69370116,"shares":108055817,"eps":-3.70325,"marketStatus":"交易中","change":5.3425,"latestTime":"05-15 15:26:56 EDT","open":223.88,"high":225.97,"low":220.865,"amount":61569627.48216,"amplitude":0.02321,"askPrice":225.53,"askSize":103,"bidPrice":224.82,"bidSize":24,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1747339200000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":219.95,"preHourTrading":{"tag":"盘前","latestPrice":222.8,"preClose":219.95,"latestTime":"09:28 EDT","volume":158,"amount":35194.24878,"timestamp":1747315680073},"postHourTrading":{"tag":"盘后","latestPrice":219.95,"preClose":219.95,"latestTime":"18:20 EDT","volume":1825,"amount":401390.1,"timestamp":1747261215490},"volumeRatio":0.717554,"impliedVol":0.4035,"impliedVolPercentile":0.163},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":69370116,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.717554,"shares":108055817,"dividePrice":0,"high":225.97,"amplitude":0.02321,"preClose":219.95,"low":220.865,"week52Low":141.31,"pbRate":"6.96","psRate":"5.83","week52High":287.88,"institutionHeld":0,"latestPrice":225.2925,"committee":-0.622047,"eps":-3.70325,"divideRate":0,"volume":275086,"delay":0,"ttmEps":-3.70325,"open":223.88,"prevYearClose":184.71,"prevWeekClose":231.99,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":235.94,"twentyDayClose":228.14,"sixtyDayClose":236.69},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531754057","title":"回港中概股午後走強，金山雲(03896.HK)漲超13%，百濟神州(06160.HK)漲超7%，萬國數據(09698.H","url":"https://stock-news.laohu8.com/highlight/detail?id=2531754057","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531754057?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 13:33","pubTimestamp":1745991202,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"02ef7766aaeb258258a594519db630be","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1502","BK1583","BK4535","BK4551","09698","03888","09991","06160","BK1526","BK1585","BK1501","TTTN","GDS","688235","BK1586","BK4503","BK4607","BK1517","03896","KC","BK4509","BK4608","BK4220","BK1589","BK1607","BK4529","ONC","BK1518","BK1249","BK4077","BK4614","BK4526","BK1531","BK1588","LU1023057109.AUD","BZ","BK4505","BK1500","BK4122","02076","BK0239","BK1142","BK4558","LU2328871848.SGD","LU0348767384.USD","LU2039709279.SGD","LU0359201612.USD","BZUN","BK4502","BK4563"],"gpt_icon":0},{"id":"2531735757","title":"A股創新藥概念持續走強，百濟神州、諾誠健華、錦波生物均創出歷史新高，科倫藥業、益方生物、澤璟製藥、華東醫藥、恆瑞醫藥等漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735757","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531735757?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 13:13","pubTimestamp":1745990033,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06978","688382","BK1588","159982","BK0175","002422","688235","BK1583","000963","BK4139","LU0405327148.USD","600276","BK0188","LU1328615791.USD","LU0588546209.SGD","LU2148510915.USD","06160","159992","BK0028","09969","BK0209","BK0060","LU1969619763.USD","BK1161","BK0012","BK0183","BK0187","BK1500","BK0196","LU1064130708.USD","399300","LU1064131003.USD","LU2328871848.SGD","BK0132","BK0239","BK1574","LU0307460666.USD","688266","LU2488822045.USD","688428","LU0405327494.USD","ONC"],"gpt_icon":0},{"id":"2531771649","title":"百濟神州：盤中漲超 5% 24 年收入增 55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531771649","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531771649?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 12:42","pubTimestamp":1745988165,"startTime":"0","endTime":"0","summary":"百济神州盘中涨超 6%，截至发稿，股价上涨 5.50%，现报 157.20 港元，成交额 5.72 亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430135427974b21a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430135427974b21a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2531560727","title":"百濟神州美股專利糾紛勝訴午盤漲近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531560727","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531560727?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 12:07","pubTimestamp":1745986022,"startTime":"0","endTime":"0","summary":"4月30日，百济神州股价午盘涨5.50%，报157.20港元。美国专利商标局宣布Pharmacyclics的‘803专利全部权利无效，公司原研药百悦泽®未侵权。去年百济神州收入38.1亿美元，同比增长55%，产品收入增长72.6%。强劲业绩得益于百悦泽®的成功及丰富的肿瘤管线，预计2025年将有多个项目数据读出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043012102594e86d2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043012102594e86d2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235","ONC","06160"],"gpt_icon":0},{"id":"2531404722","title":"【港股午評：AI股強勢，恒生科技指數漲超1%，金山雲飆升15%】截至半日收盤，恒指漲0.22%報22056點，恒生科技指數漲1.06%，國企指數跌0.37%。恒指半日成交1127億港元，南下資金半日淨買入港股34.34億港元。 首季盈利表現遜預期，內銀股集體下挫，盛京銀行跌超6%，工商銀行、郵儲銀行、招商銀行、農業銀行跌超4%，建設銀行跌近4%。 AI概念股集體走強，金山雲大漲超15%，邁富時漲超8%，第四範式漲超6%，美圖、金山軟件漲超5%，小米漲近5%。小米今天開源首個為推理(Reasoning)而生的大模型“Xiaomi MiMo”，聯動預訓練到後訓練，全面提升推理能力。 機器人概念股集體走強，微創機器人漲超9%，速騰聚創漲超7%。工信部近日表示，人形機器人是人工智能賦能新型工業化的高級載體，將推動人形機器人產業創新發展，以人形機器人小切口帶動人工智能大產業發展，高水平賦能新型工業化。 百濟神州漲超5%；美藥企專利指控被判無效。 迪生創建(0113.HK)獲主席潘迪生溢價50.6%提私有化，今日復牌大漲，半日收漲43.1%。 友邦漲近6%；首季新業務價值升13%至15億美元，香港業務新業務價值升16%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531404722","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531404722?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 12:06","pubTimestamp":1745986017,"startTime":"0","endTime":"0","summary":"恒指半日成交1127亿港元，南下资金半日净买入港股34.34亿港元。AI概念股集体走强，金山云大涨超15%，迈富时涨超8%，第四范式涨超6%，美图、金山软件涨超5%，小米涨近5%。机器人概念股集体走强，微创机器人涨超9%，速腾聚创涨超7%。百济神州涨超5%；美药企专利指控被判无效。迪生创建获主席潘迪生溢价50.6%提私有化，今日复牌大涨，半日收涨43.1%。友邦涨近6%；首季新业务价值升13%至15亿美元，香港业务新业务价值升16%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30120650034703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688235","01398","06682","LU0469268626.HKD","03968","601939","HHImain","LU1979443071.USD","601288","HSCEI","HSI","LU0456827905.SGD","LU1115378108.SGD","ONC","601398","01658","YANG","LU1242518857.USD","HSTECH","LU0384037296.USD","00113","03888","00939","01288","01357","MCHmain","LU1807302812.USD","02252","LU0259732245.USD","161631","601658","06160","513600","81810","IE00BYV24P56.USD","02833","03143","BK0188","02066","02556","HXXD.SI","600036","KSFTF"],"gpt_icon":1},{"id":"2531724435","title":"百濟神州午前漲近6% 美國專利糾紛勝訴公司去年業績取得強勁增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2531724435","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531724435?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 11:52","pubTimestamp":1745985120,"startTime":"0","endTime":"0","summary":"　　百济神州盘中涨超6%，截至发稿，股价上涨5.50%，现报157.20港元，成交额5.72亿港元。公司全年业绩取得强劲增长，充分彰显了公司作为全球肿瘤治疗领导者的实力。这得益于百悦泽的持续成功以及公司在肿瘤领域开发的最丰富的实体瘤管线之一，预计2025年将有多个项目进行数据读出。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-30/doc-ineuxfhw3485583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LU1969619763.USD","BK1500","688235","06160","LU0588546209.SGD","BK4139","ONC","LU2328871848.SGD","BK1583","BK0239","LU0307460666.USD","BK1588"],"gpt_icon":0},{"id":"2531972101","title":"港股醫藥高開低走，恒生醫藥ETF一度漲超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531972101","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531972101?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 11:45","pubTimestamp":1745984701,"startTime":"0","endTime":"0","summary":"美国专利商标局最终裁定Pharmacyclics的803专利全部权利无效，该专利此前被用于指控百济神州的百悦泽侵权。4月30日早盘，百济神州大涨超5%，带动港股医药板块上涨，恒生医药ETF（159892）一度涨超1%，持仓股方舟健客涨超10%，乐普生物、荣昌生物等跟涨。银河证券认为，医药板块经历较长时间调整，整体估值处于较低水平，且公募持仓低配，2025年在支持引导商保发展的政策背景下，支付端有望边际改善，创新药械有望获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011450394e86577&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011450394e86577&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","06160","688235"],"gpt_icon":0},{"id":"2531721243","title":"港股異動 | 百濟神州(06160)漲超6% 美國專利糾紛勝訴 公司去年業績取得強勁增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2531721243","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531721243?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 11:36","pubTimestamp":1745984193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州涨超6%，截至发稿，涨6.04%，报158港元，成交额5.47亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","06160","BK1500","BK1588","BK4139","LU0588546209.SGD","LU0307460666.USD","BK1161","LU2328871848.SGD","LU1969619763.USD","ONC","688235","BK1583"],"gpt_icon":0},{"id":"2531726021","title":"港股生物技術股多數走強，康希諾生物(06185.HK)漲超10%，百濟神州(06160.HK)漲超6%，諾誠健華(099","url":"https://stock-news.laohu8.com/highlight/detail?id=2531726021","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531726021?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 11:11","pubTimestamp":1745982713,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","07226","BK1191","BK1588","BK4614","06160","BK0239","BK1574","BK0028","BK4139","LU2328871848.SGD","HSTECH","300347","BK0077","LU1820825898.SGD","688235","LU0588546209.SGD","BK0216","BK1500","HSCEI","YANG","BK0174","LU1146622755.USD","LU1969619763.USD","ONC","BK1576","BK1161","03347","688428","06185","09969","BK1515","LU0307460666.USD","BK1141"],"gpt_icon":0},{"id":"1173388278","title":"夜盤異動丨百濟神州漲超6%，美藥企專利指控被判無效","url":"https://stock-news.laohu8.com/highlight/detail?id=1173388278","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173388278?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 10:24","pubTimestamp":1745979873,"startTime":"0","endTime":"0","summary":"4月30日，百济神州夜盘涨超6，消息方面：百济神州称美国专利商标局宣布Pharmacyclics针对百济神州的专利无效。集团宣布，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics LLC在专利授权後复审程序中受到百济神州质疑的第11,672,803号美国专利的全部权利无效。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"百济神州：美药企专利指控被判无效","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160"],"gpt_icon":0},{"id":"2531728003","title":"百濟神州4月29日成交額為7993.13萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531728003","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531728003?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 10:17","pubTimestamp":1745979436,"startTime":"0","endTime":"0","summary":"美东时间2025年4月29日，百济神州成交额为7993.13万美元，成交额较昨日增加28.30%，当日成交量为32.12万股。百济神州于2025年4月29日涨0.12%，报249.77美元，该股过去5个交易日跌1.19%，年初至今涨35.22%，过去60日涨11.01%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101725a6ce277e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101725a6ce277e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2531972824","title":"百濟神州美國專利糾紛勝訴，創新藥滬深港ETF漲超1%，創新藥龍頭拐點或現？","url":"https://stock-news.laohu8.com/highlight/detail?id=2531972824","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531972824?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 10:13","pubTimestamp":1745979209,"startTime":"0","endTime":"0","summary":"消息面，百济神州2025年4月30日公告称，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics LLC在专利授权后复审程序中受到公司质疑的第11,672,803号美国专利的全部权利无效。受利好刺激，创新药板块盘初拉升，相关ETF——创新药沪深港ETF涨超1%，年初至今涨近14%。相关机构表示，百济神州获胜意味着中国创新药国际化之路取得了阶段性胜利，这也是真正成为具有国际竞争力的MNC的必经过程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101941974ae642&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101941974ae642&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK1574","BK1583","06978","LU1969619763.USD","LU0588546209.SGD","LU2328871848.SGD","BK1161","06160","BK1588","LU0307460666.USD","BK1500","ONC"],"gpt_icon":0},{"id":"2531400737","title":"港股創新藥板塊盤初拉昇，百濟神州漲超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531400737","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531400737?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 09:48","pubTimestamp":1745977688,"startTime":"0","endTime":"0","summary":"南方财经4月30日电，港股创新药板块盘初拉升，百济神州涨超6%，石药集团、荣昌生物涨超3%，泰格医药、白云山、君实生物跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504303394091766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","YANG","BK1500","LU1969619763.USD","HSCEI","BK1574","HSTECH","LU0307460666.USD","LU2328871848.SGD","ONC","BK4614","BK1161","06160","BK1588","BK1583","BK4139","06978"],"gpt_icon":0},{"id":"2531621710","title":"百濟神州(06160)因受限制股份單位獲歸屬而發行21.47萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531621710","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531621710?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 07:53","pubTimestamp":1745970783,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年4月29日，该公司因根据股权计划授出的受限制股份单位获归属(公司董事除外)而发行21.47万股普通股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","BK1161","LU1969619763.USD","BK1583","LU2328871848.SGD","BK1588","ONC","BK1500","06160","BK0239","BK4139","LU0588546209.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2531120710","title":"百濟神州美國專利糾紛勝訴 USPTO裁定Pharmacyclics專利無效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531120710","media":"新浪港股","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531120710?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 07:47","pubTimestamp":1745970420,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics LLC在专利授权后复审程序中受到百济神州质疑的第11，672，803号美国专利的全部权利无效。\n　　2023年11月1日，针对Pharmacyclics就百悦泽®（BRUKINSA®）对百济神州提起的专利侵权诉讼，百济神州向USPTO提交了PGR申请，质疑‘803专利中某些权利的有效性。Pharmacyclics可对USPTO的最终书面决定提出上诉。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-30/doc-ineuwyyy3511637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0588546209.SGD","688235","ONC","BK1583","LU2328871848.SGD","06160","BK0239","BK1161","BK4139","BK1588","LU0307460666.USD","BK1500","LU1969619763.USD"],"gpt_icon":0},{"id":"2531710813","title":"百濟神州：關於公司涉及訴訟的進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2531710813","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531710813?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 07:37","pubTimestamp":1745969847,"startTime":"0","endTime":"0","summary":"金融界4月30日消息，百济神州公告称，2023 年 6 月 13 日，Pharmacyclics LLC 公司在美国特拉华州地方法院对百济神州有限公司及公司全资子公司提出申诉，声称公司产品百悦泽®侵犯其专利。2025 年 4 月 29 日，USPTO 作出最终书面决定，宣布 Pharmacyclics 在 PGR 程序中受到公司质疑的‘803 专利的全部权利无效。Pharmacyclics 可提起上诉。本次诉讼目前未对百悦泽®在美国的研发和销售产生不利影响，且预计不会对公司的生产经营产生重大不利影响。\n\n\r\n            责任编辑：栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/30073750025781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0307460666.USD","688235","LU1969619763.USD","LU0588546209.SGD","BK1500","BK4139","LU2328871848.SGD","BK1161","06160","ONC","BK0239","BK1588","BK1583"],"gpt_icon":0},{"id":"2531127427","title":"百濟神州(06160)美國專利糾紛勝訴 USPTO裁定Pharmacyclics專利無效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531127427","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531127427?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 07:21","pubTimestamp":1745968909,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics LLC在专利授权后复审程序中受到百济神州质疑的第11,672,803号美国专利的全部权利无效。2023年11月1日，针对Pharmacyclics就百悦泽®(BRUKINSA®)对百济神州提起的专利侵权诉讼，百济神州向USPTO提交了PGR申请，质疑‘803专利中某些权利的有效性。Pharmacyclics可对USPTO的最终书面决定提出上诉。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4139","06160","LU2328871848.SGD","BK1583","688235","LU0307460666.USD","BK0239","BK1161","LU1969619763.USD","BK1500","LU0588546209.SGD","ONC"],"gpt_icon":0},{"id":"2531200277","title":"索托克拉上市申請獲受理，百濟神州血液腫瘤管線或迎又一重磅新品","url":"https://stock-news.laohu8.com/highlight/detail?id=2531200277","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531200277?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 17:24","pubTimestamp":1745918697,"startTime":"0","endTime":"0","summary":"国家药品监督管理局药品审评中心昨天正式受理百济神州在研BCL2抑制剂索托克拉片的新药上市申请，并已纳入优先审评程序，拟用于治疗既往接受过治疗的慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者。索托克拉是百济神州自主研发的新一代BCL2抑制剂，也是百济神州继泽布替尼之后有望面市的又一款血液肿瘤的自研产品，有望进一步夯实百济神州在CLL/SLL治疗领域的研发实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504293392945536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","LU1969619763.USD","LU0588546209.SGD","LU2328871848.SGD","BK1588","06160","BK4139","ONC","BK1161","BK1583","LU0307460666.USD"],"gpt_icon":0},{"id":"2531271089","title":"索托克拉上市申請獲受理 百濟神州又一款血液腫瘤自研產品有望面市","url":"https://stock-news.laohu8.com/highlight/detail?id=2531271089","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531271089?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 16:28","pubTimestamp":1745915280,"startTime":"0","endTime":"0","summary":"索托克拉是百济神州自主研发的新一代BCL2抑制剂，也是百济神州继泽布替尼之后有望面市的又一款血液肿瘤的自研产品，或将进一步夯实百济神州在CLL/SLL治疗领域的研发实力。资料显示，CLL是一种危及生命的B淋巴细胞恶性肿瘤，是成人血液肿瘤最常见的类型之一。索托克拉作为百济神州自主研发的新一代 BCL2 抑制剂，旨在阻断可帮助肿瘤细胞存活的BCL2蛋白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042916381294e73c09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042916381294e73c09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK0239","ONC"],"gpt_icon":0},{"id":"2531573242","title":"百濟神州2024年虧損減少至49.8億元，收入增長56.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531573242","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531573242?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 12:48","pubTimestamp":1745902091,"startTime":"0","endTime":"0","summary":"4月28日，百济神州(688235)公布2024年年报，公司营业收入为272.1亿元，同比上升56.2%；归母净利润自去年同期亏损67.2亿元变为亏损49.8亿元，亏损额有所减少；扣非归母净利润自去年同期亏损96.8亿元变为亏损53.8亿元，亏损额有所减少；经营现金流净额为-12.59亿元，同比增长83.8%；EPS(全面摊薄)为-3.5948元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504293392632734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1588","LU2328871848.SGD","LU0307460666.USD","BK1161","LU0588546209.SGD","ONC","06160","BK4139","BK1500","LU1969619763.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-14","current":-61.889623,"percent":0.044944,"low":-64.911375,"twenty":-43.424174,"median":-39.182934,"eighty":-28.820246,"high":-22.805663,"avg":-37.41726,"sd":9.466346,"marketCap":24283383754},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595},{"date":"2025-05-14","current":-61.889623,"twenty":-43.424174,"median":-39.182934,"eighty":-28.820246,"marketCap":24283383754}],"updateTime":1747314222968}}}